- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01978548
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
June 24, 2015 updated by: Janssen Research & Development, LLC
A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Aβ Processing in CSF and Plasma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a multicenter, double-blind (neither investigator nor patient knows which treatment the patient receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), randomized (patients are assigned different treatments based on chance), multiple-dose, proof-of-mechanism (POM) study in pAD.
Approximately 24 outpatients (n=8/treatment group) diagnosed with pAD, according to the inclusion and exclusion criteria, will participate in this 4-week treatment study.
For all enrolled patients, this study will consist of an 8-week eligibility screening period, a 4-week double-blind treatment period, and a follow-up examination (7-14 days after the last dose).
Patients will be assigned randomly to 1 of 3 treatment groups: placebo, JNJ-54861911 10 mg once daily, or JNJ-54861911 50 mg once daily.
Safety assessments will be performed throughout the study.
The maximal study duration for a patient will be 14 weeks.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Antwerp, Belgium
-
Gent, Belgium
-
Hoboken, Belgium
-
-
-
-
-
Amsterdam, Netherlands
-
-
-
-
-
Barcelona, Spain
-
Madrid, Spain
-
Madrid N/A, Spain
-
Terrassa, Spain
-
Valencia, Spain
-
-
-
-
-
Mölndal, Sweden
-
Stockholm, Sweden
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have had sufficient education or work experience to exclude mental retardation
- Patients must have an abnormal cognitive performance consistent with mild cognitive impairment based on the computerized neuropsychological test battery (CANTAB Elect) that can effectively screen patients and identify cognitive deficits consistent with mild cognitive impairment
- Patients must have evidence of amyloid deposition by means of either 1) low cerebrospinal fluid amyloid beta 1-42 (CSF amyloid beta 1-42) levels and elevated CSF p-Tau and/or total tau levels at screening (cut off values for CSF amyloid beta 1-42 and CSF p-tau and/or total tau will be based on the values established by the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden and specified in a separate lab manual) or 2) a positive 18F-flutematol amyloid positron emission tomography (PET) amyloid scan at screening (optional depending on the site's PET capability) or both
- Patients must have a body mass index (BMI=weight/height²) between 18 and 35 kg/m2, inclusive, at screening
- Women must be postmenopausal, permanently sterilized or otherwise be incapable of pregnancy
- Must adhere to required contraception during and for 3 months after study
- Patients must be otherwise healthy for their age group or medically stable with or without medication
- Patients must be able to be compliant with self-administration of medication
- Patients must be able to swallow drug as a whole
Exclusion Criteria:
- Patient has evidence of brain disease, other than Alzheimer's Disease (AD), or any other abnormality (e.g. folic acid/Vitamin B12 deficiency) that could explain the cognitive deficit (including, but not limited to vascular encephalopathy or strokes, as imaged by cerebral MRI and Major Depression, as defined by DSM-IV criteria)
- Patient has been diagnosed with dementia due to AD, due to other diseases, or with AD and contribution of other disorders (mixed dementia)
- Patient has evidence of familial autosomal dominant AD
- Patient has a history of substance or alcohol abuse
- Relevant history of lower back pain or scoliosis and/or major (lumbar) back surgery
- Patient is allergic to local anesthetics and/or iodine or chlorhexidine
- Patient has taken aspirin (even low dose) within 5 days prior to lumbar puncture (screening or Day 1)
- Patient has taken Low Molecular Weight Heparin (LMWH) within 12 hours prior to lumbar puncture (screening or Day 1)
- Patient has taken any anticoagulant treatment (e.g. warfarin; besides LMWH described above) within 1 week prior to lumbar puncture (screening or Day 1)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: JNJ-54861911 10 mg
From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
|
JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
|
EXPERIMENTAL: JNJ-54861911 50 mg
|
JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
|
PLACEBO_COMPARATOR: Placebo
Patients will receive matching placebo.
|
Matching placebo will be administered as 2 oral tablets once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of amyloid beta 1-40 in cerebrospinal (CSF) after treatment at the intended target dose range
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
|
Levels of amyloid beta 1-40 in plasma after treatment at the intended target dose range
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
|
Maximum observed plasma concentration (Cmax) of JNJ-54861911
Time Frame: Up to 4 weeks
|
Cmax is the observed maximum plasma concentration of study drug, taken directly from the plasma concentration-time profile
|
Up to 4 weeks
|
Time to reach maximum observed plasma concentration of JNJ-54861911
Time Frame: Up to 4 weeks
|
Time when Cmax is observed, taken directly from the plasma concentration-time profile
|
Up to 4 weeks
|
Area under the plasma concentration time curve (AUC) from 0 to t hours of JNJ-54861911
Time Frame: Up to 4 weeks
|
Area under the plasma concentration-time curve from 0 to t hours post dosing (time t is the dosing interval)
|
Up to 4 weeks
|
Half-life of JNJ-54861911
Time Frame: Up to 4 weeks
|
Elimination half-life associated with the terminal slope of the semi-logarithmic drug concentration-time curve, calculated as 0.693/terminal slope
|
Up to 4 weeks
|
Cerebrospinal fluid exposure of JNJ-54861911
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
|
The number of volunteers who experience adverse events as a measure of safety and tolerability of JNJ-54861911 after multiple-dose administration in the anticipated target dose range
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Levels of amyloid beta fragments (amyloid beta 1-37, 1-38, and 1-42) in cerebrospinal fluid after treatment at the intended target dose range
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Levels of amyloid beta fragments (amyloid beta 1-37, 1-38, and 1-42) in plasma after treatment at the intended target dose range
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Levels of amyloid precursor protein (APP) fragments (soluble amyloid precursor protein α [sAPPalpha], sAPPbeta, totalAPP) in CSF after treatment at the intended target dose range
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Compare the relationship of amyloid beta 1-40 levels in plasma and cerebrospinal fluid after treatment at the intended target dose range
Time Frame: Up to 4 weeks
|
Up to 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (ACTUAL)
April 1, 2015
Study Completion (ACTUAL)
April 1, 2015
Study Registration Dates
First Submitted
October 31, 2013
First Submitted That Met QC Criteria
October 31, 2013
First Posted (ESTIMATE)
November 7, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
June 25, 2015
Last Update Submitted That Met QC Criteria
June 24, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR103012
- 54861911ALZ1005 (OTHER: Janssen Research & Development, LLC)
- 2013-003036-69 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on JNJ-54861911 10 mg
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCTerminatedAlzheimer DiseaseFrance, Spain, Netherlands, Belgium, Germany, Sweden
-
Janssen Research & Development, LLCCompletedAlzheimer's DiseaseFrance, Spain, Netherlands, Belgium, Germany, Sweden
-
Janssen Pharmaceutical K.K.Completed
-
Janssen Research & Development, LLCCompleted
-
Janssen Pharmaceutical K.K.Completed
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen-Cilag International NVCompleted